Skip to main content
Signal8
Chandru Vijay profile photo

Vijay Chandru

CIK: 0001813367

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)2 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

Lantern Pharma Inc. logo
LTRN

Lantern Pharma Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

  • Lantern Pharma Inc. logo
    LTRN

    Lantern Pharma Inc.

    Jan 9, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    25K shares-
  • Lantern Pharma Inc. logo
    LTRN

    Lantern Pharma Inc.

    Jan 9, 2026
    Award(A)

    Stock Option (Right to Buy)

    Direct
    17.3K shares-
  • Lantern Pharma Inc. logo
    LTRN

    Lantern Pharma Inc.

    Nov 4, 2021
    Disposition(D)

    Stock Option (Right to Buy)

    Direct
    3.2K shares-
  • Lantern Pharma Inc. logo
    LTRN

    Lantern Pharma Inc.

    Nov 4, 2021
    Award(A)

    Stock Option (Right to Buy)

    Direct
    3.2K shares-
  • Lantern Pharma Inc. logo
    LTRN

    Lantern Pharma Inc.

    Jun 15, 2020
    Disposition(D)

    Stock Option (Right to Buy)

    Direct
    9.1K shares-
  • Lantern Pharma Inc. logo
    LTRN

    Lantern Pharma Inc.

    Jun 15, 2020
    Award(A)

    Stock Option (Right to Buy)

    Direct
    9.1K shares-

1-6 of 6

About Chandru Vijay

Chandru Vijay (SEC CIK 0001813367) files insider reports with the SEC as Director of Lantern Pharma Inc. (LTRN).

Signal8 holds 2 ownership filings by Chandru Vijay, all Form 4s, filed between Sep 23, 2025 and Jan 13, 2026. Those filings report 6 transactions, from Jun 15, 2020 to Jan 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Chandru Vijay's filings is in DALLAS, TX.

Recent filings by Chandru Vijay

  • Jan 9, 2026: Grants or awards of LTRN derivative securities (2 lines, Form 4, code A).
  • Nov 4, 2021: Disposition to issuer transaction of LTRN derivative securities (Form 4, code D).
  • Nov 4, 2021: Grant or award of LTRN derivative securities (Form 4, code A).
  • Jun 15, 2020: Disposition to issuer transaction of LTRN derivative securities (Form 4, code D).
  • Jun 15, 2020: Grant or award of LTRN derivative securities (Form 4, code A).

Other insiders filing for Lantern Pharma Inc. (LTRN)

How to read Form 4 transaction codes